Canakinumab Subcutaneous and Fluticasone, umeclidinium, and vilanterol Inhalation
Determining the interaction of Canakinumab Subcutaneous and Fluticasone, umeclidinium, and vilanterol Inhalation and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: canakinumab
Brand name: Ilaris
Synonyms: Canakinumab
Generic Name: fluticasone / umeclidinium / vilanterol
Brand name: Trelegy Ellipta
Synonyms: Fluticasone, umeclidinium, and vilanterol, Umeclidinium, and Vilanterol
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Canakinumab Subcutaneous-Flutone
- Canakinumab Subcutaneous-FluTuss XP Oral
- Canakinumab Subcutaneous-Fluvastatin
- Canakinumab Subcutaneous-Fluvastatin Capsules
- Canakinumab Subcutaneous-Fluvastatin ER Tablets
- Canakinumab Subcutaneous-Fluvastatin Extended-Release Tablets
- Fluticasone, umeclidinium, and vilanterol Inhalation-Canasa
- Fluticasone, umeclidinium, and vilanterol Inhalation-Canasa Pac rectal
- Fluticasone, umeclidinium, and vilanterol Inhalation-Canasa rectal
- Fluticasone, umeclidinium, and vilanterol Inhalation-Cancidas
- Fluticasone, umeclidinium, and vilanterol Inhalation-Candesartan
- Fluticasone, umeclidinium, and vilanterol Inhalation-Candesartan and Hydrochlorothiazide